Business Description
Immutep Ltd
ISIN : AU000000IMM6
Total Employee Number:
51Description
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 81.93 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -3.4 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | -6.1 | |||||
3-Year Book Growth Rate | -2.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.46 | |||||
9-Day RSI | 56.88 | |||||
14-Day RSI | 53.53 | |||||
3-1 Month Momentum % | 20.51 | |||||
6-1 Month Momentum % | -89.78 | |||||
12-1 Month Momentum % | -80.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.97 | |||||
Quick Ratio | 2.97 | |||||
Cash Ratio | 2.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18 | |||||
Shareholder Yield % | 0.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year ROIIC % | -13441.38 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
Forward PE Ratio | 7.8 | |||||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
PB Ratio | 0.83 | |||||
Price-to-Tangible-Book | 0.92 | |||||
EV-to-EBIT | 0.27 | |||||
EV-to-Forward-EBIT | 5.49 | |||||
EV-to-EBITDA | 0.27 | |||||
EV-to-Forward-Revenue | 15.65 | |||||
EV-to-FCF | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 0.92 | |||||
| Price-to-Net-Cash | 1.83 | |||||
Earnings Yield (Greenblatt) % | 365.06 | |||||
FCF Yield % | -41.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immutep Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | - | ||
| Beta | 2.2361 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.2 | ||
| Volatility % | 106.35 | ||
| 14-Day RSI | 53.53 | ||
| 14-Day ATR (A$) | 0.004299 | ||
| 20-Day SMA (A$) | 0.05265 | ||
| 12-1 Month Momentum % | -80.82 | ||
| 52-Week Range (A$) | 0.028 - 0.47 | ||
| Shares Outstanding (Mil) | 1,473.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immutep Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immutep Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-27 11:30 | In 137 days | ||
| Annual report for 2026 | 2026-08-28 | In 45 days | ||
| Fourth quarter earnings results for 2026 | 2026-07-30 | In 16 days | ||
| Second quarter earnings results for 2026 | 2026-01-29 | 0.44 (-2.22%) | ||
| General meeting for 2025 | 2025-11-27 11:30 | 0.27 (+0.00%) | ||
| Annual report for 2025 | 2025-08-29 | 0.25 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-07-30 | 0.27 (-1.82%) | ||
| Second quarter earnings results for 2025 | 2025-02-26 | 0.31 (+1.64%) | ||
| General meeting for 2024 | 2024-11-22 10:30 | 0.29 (-6.56%) | ||
| Guidance call for 2024 | 2024-11-14 | 0.31 (+1.64%) |
Show
Entries
Immutep Ltd Frequently Asked Questions
What is Immutep Ltd(ASX:IMM)'s stock price today?
The current price of ASX:IMM is A$0.06. The 52 week high of ASX:IMM is A$0.47 and 52 week low is A$0.03.
When is next earnings date of Immutep Ltd(ASX:IMM)?
The next earnings date of Immutep Ltd(ASX:IMM) is 2026-07-30 Est..
Does Immutep Ltd(ASX:IMM) pay dividends? If so, how much?
Immutep Ltd(ASX:IMM) does not pay dividend.
Press Release
Articles on Immutep Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers